Clinical Trials Browser

Interventional × Epstein-Barr Virus Infections × 30 days × Clear all

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT07614282 2026-05-29

Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia

Phase 1 Not yet recruiting

28 enrolled

Infections, Epstein-Barr Virus Infections

NCT04364178 2026-05-27

Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV

Phase 1/2 Terminated

8 enrolled 14 charts

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT03258567 2026-05-22

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Phase 2 Recruiting

40 enrolled

Lymphoid

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT03394365 2026-05-22

ALLELE

Phase 3 Recruiting

115 enrolled

Lymphoid

Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT06908096 2026-05-18

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

Phase 1 Recruiting

750 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Phase 2/3 Active not recruiting

685 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05164094 2026-05-06

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

Phase 1/2 Active not recruiting

867 enrolled